Alnylam Pharmaceuticals Surges to 439th in Trading Volume with $185 Million Turnover

On April 21, 2025, Alnylam Pharmaceuticals (ALNY) experienced a significant trading day with a turnover of $185 million, marking a 31.78% increase from the previous day. This surge placed ALNY at the 439th position in terms of trading volume for the day. However, the stock closed with a slight decline of 0.77%.

Analysts have shown a strong bullish sentiment towards Alnylam Pharmaceuticals. Over the past three months, 22 analysts have rated the stock, with 18 recommending a 'Buy' and 4 suggesting a 'Hold'. There are no 'Sell' ratings. This consensus reflects a positive outlook on the company's future performance.

The average 12-month price target for Alnylam Pharmaceuticals is $321.86, indicating a potential upside of 37.22% from the current price. The highest price target among analysts is $500.00, while the lowest is $206.00. This wide range suggests varying levels of optimism about the stock's potential growth.

Several analysts have reiterated their positive stance on Alnylam Pharmaceuticals. For instance, Piper Sandler maintained a 'Buy' rating with a price target of $304, representing a 29.60% upside. Similarly, Bernstein reiterated a 'Buy' rating with a price target of $305, indicating a 30.03% upside. J.P. Morgan upgraded Alnylam Pharmaceuticals to 'Overweight' from 'Neutral', with a price target increased from $280 to $328, reflecting a 39.84% upside.

TD Cowen also reiterated a 'Buy' rating with a price target of $371, suggesting a 58.17% upside. These ratings underscore the confidence analysts have in Alnylam Pharmaceuticals' growth prospects, driven by recent FDA approvals and promising clinical results.